

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 -46. (Cancelled)

47. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form $-C(R_5)=N-$;

Y is $-C(R_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R₁ is absent;

Y' is $-N(R_5)-$;

Z forms a covalent single bond between X' and Y';

R₂ and R₄ are independently selected from hydrogen and C₁₋₃alkyl;

R₃ is selected from C₁₋₃alkyl and (A)_mR₁₂;

$-C(R_5)-$ is selected from $-C(H)-$ and $-C(C_{1-20}alkyl)-$;

$-N(R_5)-$ is selected from $-N(H)-$ and $-N(C_{2-20}alkyl)-$;

m is 0;


AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

R_{12} is selected from the group consisting of OH, SH, NH_2 , halo, NO_2 , $\text{C}(\text{R}_{17})_3$, $\text{OC}(\text{R}_{17})_3$ and CN; and

R_{17} is independently selected from hydrogen and halogen; ~~and~~

~~wherein each alkyl may be optionally substituted.~~

48. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or ~~prodrug~~ thereof



wherein

X and X' taken together form $-\text{C}(\text{R}_5)=\text{N}-$;

Y is $-\text{C}(\text{R}_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R_1 is absent;

Y' is $-\text{N}(\text{R}_5)-$;

Z forms a covalent single bond between X' and Y';

R_2 and R_4 are independently selected from hydrogen and C_{1-3} alkyl;

R_3 is selected from C_{1-3} alkyl and $(\text{A})_m\text{R}_{12}$;

$-\text{C}(\text{R}_5)-$ is selected from $-\text{C}(\text{H})-$ and $-\text{C}(\text{C}_{1-20}\text{alkyl})-$;

$-\text{N}(\text{R}_5)-$ is selected from $-\text{N}(\text{alkyl})-$ wherein alkyl is selected from the group consisting of ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *t*-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

m is 0;

R₁₂ is selected from the group consisting of OH, SH, NH₂, halo, NO₂, C(R₁₇)₃, OC(R₁₇)₃ and CN;

R₁₇ is independently selected from hydrogen and halogen; and
wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is -CH-; and

X is -CH-.

50. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is OC(R₁₇)₃.

51. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is C₁₋₃alkyl.

52. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is -CH₃ or -OCH₃.

53. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R₅)- is -N(3-methylbutyl).

54. (Previously presented) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (Previously presented) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (Previously presented) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (Previously presented) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.